ATE190355T1 - Genexpressions-elemente und herstellung von chimären maus-mensch-antikörpern - Google Patents

Genexpressions-elemente und herstellung von chimären maus-mensch-antikörpern

Info

Publication number
ATE190355T1
ATE190355T1 AT89309048T AT89309048T ATE190355T1 AT E190355 T1 ATE190355 T1 AT E190355T1 AT 89309048 T AT89309048 T AT 89309048T AT 89309048 T AT89309048 T AT 89309048T AT E190355 T1 ATE190355 T1 AT E190355T1
Authority
AT
Austria
Prior art keywords
production
gene expression
expression elements
human antibodies
chimeric mouse
Prior art date
Application number
AT89309048T
Other languages
English (en)
Inventor
Marc D Better
Arnold H Horwitz
Randy R Robinson
Shau-Ping Lei
Changtung Paul Chang
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Application granted granted Critical
Publication of ATE190355T1 publication Critical patent/ATE190355T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT89309048T 1988-09-06 1989-09-06 Genexpressions-elemente und herstellung von chimären maus-mensch-antikörpern ATE190355T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US24062488A 1988-09-06 1988-09-06
US24174488A 1988-09-08 1988-09-08
US24373988A 1988-09-13 1988-09-13
US25300288A 1988-10-04 1988-10-04
US36764189A 1989-06-19 1989-06-19
US38276889A 1989-07-21 1989-07-21

Publications (1)

Publication Number Publication Date
ATE190355T1 true ATE190355T1 (de) 2000-03-15

Family

ID=27559300

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89309048T ATE190355T1 (de) 1988-09-06 1989-09-06 Genexpressions-elemente und herstellung von chimären maus-mensch-antikörpern

Country Status (9)

Country Link
US (1) US6461824B1 (de)
EP (2) EP0364096B1 (de)
AT (1) ATE190355T1 (de)
AU (1) AU643189B2 (de)
CA (1) CA1341351C (de)
DE (1) DE68929167T2 (de)
ES (1) ES2146572T3 (de)
GR (1) GR3033630T3 (de)
WO (1) WO1990002569A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576184A (en) * 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
ES2146572T3 (es) 1988-09-06 2000-08-16 Xoma Technology Ltd Elementos de expresion genica y la produccion de anticuerpos quimericos de raton-ser humano.
IL89490A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Chimeric antibodies directed against metal chelates
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0404003A3 (de) * 1989-06-19 1991-10-16 Xoma Corporation Chimäre Maus-Mensch-KM10-Antikörper, spezifisch für ein menschliches Tumorzellen-Antigen
US5580774A (en) * 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen
AU662311B2 (en) * 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
US20050196400A1 (en) * 1991-05-06 2005-09-08 Xoma Technology Ltd. Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US6037121A (en) * 1995-12-08 2000-03-14 University Technologies International Inc. DNA sequence encoding a tumor suppressor gene
US6117633A (en) * 1995-12-08 2000-09-12 University Technologies International Inc. DNA sequence encoding the tumor suppressor gene ING1
US6747133B1 (en) 1995-12-08 2004-06-08 University Technologies International Inc. Antibodies against the tumor suppressor gene ING1
US6143522A (en) * 1995-12-08 2000-11-07 University Technologies International, Inc. Methods of modulating apoptosis
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
JP2005522192A (ja) 2001-07-19 2005-07-28 パーラン セラピューティクス， インコーポレイテッド マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
EP1482043A4 (de) * 2002-03-01 2005-08-10 Japan Enviro Chemicals Ltd Zur bindung an umwelthormone fähige proteine und verfahren zur herstellung davon
US20050009097A1 (en) * 2003-03-31 2005-01-13 Better Marc D. Human engineered antibodies to Ep-CAM
US20050138692A1 (en) * 2003-06-02 2005-06-23 Biotechnology Foundation, Inc. Production of cancer-specific antibodies in plants
WO2006012414A2 (en) * 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Novel polyadenylation signal for use in expression vectors
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
PE20090499A1 (es) * 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
EP2262832A4 (de) * 2008-02-01 2011-03-09 Ca Minister Health & Welfare Monoklonale antikörper gegen ebola- und marburg-viren
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
US8992915B2 (en) 2012-05-16 2015-03-31 Boehringer Ingelheim International Gmbh Combination of CD37 antibodies with ICE
SG10201609535TA (en) * 2012-06-05 2017-01-27 Regeneron Pharma Methods for making fully human bispecific antibodies using a common light chain
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
US10836810B2 (en) 2017-02-17 2020-11-17 Mapp Biopharmaceutical, Inc. Monoclonal antibodies and cocktails for treatment of ebola infections

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612282A (en) * 1981-12-15 1986-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies reactive with human breast cancer
US4818709A (en) 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60224492A (ja) * 1984-04-24 1985-11-08 Yuu Honshiyo 異種遺伝子の結合法
EP0173494A3 (de) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
JPS61167699A (ja) * 1985-01-19 1986-07-29 Green Cross Corp:The モノクロ−ナル抗体
DE3689123T2 (de) * 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
CA1341281C (en) 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
GB2197321B (en) * 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4816282A (en) * 1987-09-30 1989-03-28 Lonza Inc. Moisture-stabilized foods having improved shelf life
CA1340221C (en) 1988-01-29 1998-12-15 Thomas Frank Bumol Vectors, compounds and method for expression of a human adenocarcinoma antigen
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
ES2146572T3 (es) 1988-09-06 2000-08-16 Xoma Technology Ltd Elementos de expresion genica y la produccion de anticuerpos quimericos de raton-ser humano.
JPH04501266A (ja) 1988-10-12 1992-03-05 セントコアー，インコーポレーテッド ヨード―１２５で標識された放射線療法用接合体
WO1993008298A1 (en) 1991-10-18 1993-04-29 The Wistar Institute Of Anatomy And Biology Soluble variants of type i membrane proteins, and methods of using them

Also Published As

Publication number Publication date
WO1990002569A1 (en) 1990-03-22
AU4402189A (en) 1990-04-02
ES2146572T3 (es) 2000-08-16
EP0364096A2 (de) 1990-04-18
US6461824B1 (en) 2002-10-08
DE68929167D1 (de) 2000-04-13
EP0364096B1 (de) 2000-03-08
AU643189B2 (en) 1993-11-11
GR3033630T3 (en) 2000-10-31
DE68929167T2 (de) 2000-11-16
EP0967277A3 (de) 2003-10-15
EP0967277A2 (de) 1999-12-29
EP0364096A3 (de) 1992-08-05
CA1341351C (en) 2002-03-26

Similar Documents

Publication Publication Date Title
DE68929167D1 (de) Genexpressions-Elemente und Herstellung von chimären Maus-Mensch-Antikörpern
IL84285A (en) Chimeric antibody with specificity to human tumor antigen
ATE112802T1 (de) Herstellung von funktionellen menschlichen urokinasepolypeptiden.
DE3751922D1 (de) Herstellung und Verwendung von IL-6
DK69890D0 (da) Monoklonale antistoffer, der er reaktive med cachetin
ATE188486T1 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
NO166943C (no) Analogifremgangsmaate for fremstilling av enzymresistente immunomodulerende peptider.
DE3579288D1 (de) Herstellung von hochaktiven wasserstoffbehandlungskatalysatoren mit kieselsaeuretraeger und die so erhaltenen katalysatoren.
EP0274394A3 (de) Chimären Antikörper, spezifisch für menschlichen B-Zellen-Oberflächenantigen
DE69334211D1 (de) Multidrug resistenz gen
DE3581400D1 (de) Maus/mensch-hybridoma mit erzeugung von antiviralen menschlichen antikoerpern, deren herstellung und antivirale menschliche monoklonale antikoerper.
EP0404003A3 (de) Chimäre Maus-Mensch-KM10-Antikörper, spezifisch für ein menschliches Tumorzellen-Antigen
PT86552A (de) Gama-glutamyl-transpeptidase deren herstellung und deren verwendung
NO981454D0 (no) Anti-FAS-antistoffer
ES8800725A1 (es) Un procedimiento para producir un anticuerpo monoclonal
DE69033810D1 (de) Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
DE3850933D1 (de) Anticoagulatorisches Protein PP4-X, seine Herstellung und Verwendung.
SU572590A1 (ru) Струйный усилитель
SU571521A1 (ru) Способ термической обработки листовых деталей
SU668725A1 (ru) Сито
Staleva The auditory set: A problem of music education.
ATE103634T1 (de) Landwirtschaftchemikalien erzeugende endosymbiotische mikroorganismen und deren herstellung und verwendung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee